[Do new oral therapies show advantages in the basal therapy of multiple sclerosis? Con]
Nervenarzt
.
2015 Apr;86(4):492-4.
doi: 10.1007/s00115-014-4246-9.
[Article in German]
Author
R A Linker
1
Affiliation
1
Neurologische Klinik, Universitätsklinikum Erlangen, Schwabachanlage 6, 91052, Erlangen, Deutschland, ralf.linker@uk-erlangen.de.
PMID:
25694252
DOI:
10.1007/s00115-014-4246-9
No abstract available
MeSH terms
Administration, Oral
Evidence-Based Medicine
Humans
Immunosuppressive Agents / administration & dosage*
Multiple Sclerosis / diagnosis*
Multiple Sclerosis / drug therapy*
Treatment Outcome
Substances
Immunosuppressive Agents